Real World Study to Evaluate the Efficacy and Resistant Mechanism of Erlotinib/Gefitinib Combined With Bevacizumab in First Line EGFR Mutation Positive Advanced Non-aquamous Non-small Cell Lung Cancer
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
This study aims to explore the efficacy and safety of Erlotinib/Gefitinib combined with bevacizumab in the real world for advanced non-squamous cell lung cancer with EGFR mutation, explore new drug resistance mechanisms under the A+T regimen and consistency between plasma and tissue detection driving genes, and finally assess the predictive value of plasma dynamic detection driving gene mutation profiles in predicting disease. The role of disease progression risk.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• EGFR mutation(19del/L858R)
• advanced non-saquamous non-small cell lung cancer
• primary treatment of first diagnosis
• performance status（0-1)
Locations
Other Locations
China
Hunan Provincal Tumor Hospital
RECRUITING
Changsha
Contact Information
Primary
Yongchang Z MD, MD
zhangyongchang@csu.edu.cn
+8613873123436
Backup
Yongchang Z MD, PhD
zhangyongchang@csu.edu.cn
+8613873123436
Time Frame
Start Date: 2018-06-01
Estimated Completion Date: 2025-12-01
Participants
Target number of participants: 30
Treatments
Cohorts 1
patients with EGFR mutation-positive who received treatment of Erlotinib/Gefitinib Combined With Bevacizumab
Related Therapeutic Areas
Sponsors
Leads: Hunan Province Tumor Hospital